Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2016-03, Vol.67 (3), p.532-533 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 533 |
|---|---|
| container_issue | 3 |
| container_start_page | 532 |
| container_title | American journal of kidney diseases |
| container_volume | 67 |
| creator | Habbig, Sandra, MD Bergmann, Carsten, MD Weber, Lutz T., MD |
| description | |
| doi_str_mv | 10.1053/j.ajkd.2015.11.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768559755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0272638615014183</els_id><sourcerecordid>1768559755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-f94fa9850ae38f9660df9f5399fee6036a9f3f33e533294268f73b1c97b206093</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhosoznX0D7iQLN205qNJGxBhuPNxhRGFcXAZctMTTG_bXJNUqL_edO7owoWrszjv-8B5TlG8JrgimLN3faX7Q1dRTHhFSIWxfFJsCKesFC1rnxYbTBtaCtaKs-JFjD3OCSbE8-KMiobWRDSb4nDpovFTctOsk_MT8hZdmXlwv-ZR75GbkEZf8gamhL659B1dpOXojB7QDkY_LMkZdB9gzONumbrgR0CXM6Dkc_HTnE7QjNle714Wz6weIrx6nOfF_fXV1-2uvP1883F7cVuampBUWllbLVuONbDWSiFwZ6XlTEoLIDATWlpmGQPOGJU1Fa1t2J4Y2ewpFvnE8-LtiXsM_scMMakxHwnDoCfwc1SkES3nsuE8R-kpaoKPMYBVx-BGHRZFsFolq16tktUqWRGi8AP_zSN_3o_Q_a38sZoD708ByFf-dBBUNNmggc4FMEl13v2f_-GfuhnctEo_wAKx93OYsj9FVKQKq7v1zeuXCcekJi1jvwEwxaGV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768559755</pqid></control><display><type>article</type><title>Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Habbig, Sandra, MD ; Bergmann, Carsten, MD ; Weber, Lutz T., MD</creator><creatorcontrib>Habbig, Sandra, MD ; Bergmann, Carsten, MD ; Weber, Lutz T., MD</creatorcontrib><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2015.11.009</identifier><identifier>PMID: 26724167</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Monoclonal, Humanized - administration & dosage ; Atypical Hemolytic Uremic Syndrome - drug therapy ; Atypical Hemolytic Uremic Syndrome - genetics ; Atypical Hemolytic Uremic Syndrome - physiopathology ; Complement Factor H - genetics ; Humans ; Immunologic Factors - administration & dosage ; Mutation ; Nephrology ; Pharmacogenetics - methods ; Precision Medicine ; Secondary Prevention ; Withholding Treatment</subject><ispartof>American journal of kidney diseases, 2016-03, Vol.67 (3), p.532-533</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2016 National Kidney Foundation, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-f94fa9850ae38f9660df9f5399fee6036a9f3f33e533294268f73b1c97b206093</citedby><cites>FETCH-LOGICAL-c411t-f94fa9850ae38f9660df9f5399fee6036a9f3f33e533294268f73b1c97b206093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2015.11.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26724167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Habbig, Sandra, MD</creatorcontrib><creatorcontrib>Bergmann, Carsten, MD</creatorcontrib><creatorcontrib>Weber, Lutz T., MD</creatorcontrib><title>Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Atypical Hemolytic Uremic Syndrome - drug therapy</subject><subject>Atypical Hemolytic Uremic Syndrome - genetics</subject><subject>Atypical Hemolytic Uremic Syndrome - physiopathology</subject><subject>Complement Factor H - genetics</subject><subject>Humans</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Mutation</subject><subject>Nephrology</subject><subject>Pharmacogenetics - methods</subject><subject>Precision Medicine</subject><subject>Secondary Prevention</subject><subject>Withholding Treatment</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhosoznX0D7iQLN205qNJGxBhuPNxhRGFcXAZctMTTG_bXJNUqL_edO7owoWrszjv-8B5TlG8JrgimLN3faX7Q1dRTHhFSIWxfFJsCKesFC1rnxYbTBtaCtaKs-JFjD3OCSbE8-KMiobWRDSb4nDpovFTctOsk_MT8hZdmXlwv-ZR75GbkEZf8gamhL659B1dpOXojB7QDkY_LMkZdB9gzONumbrgR0CXM6Dkc_HTnE7QjNle714Wz6weIrx6nOfF_fXV1-2uvP1883F7cVuampBUWllbLVuONbDWSiFwZ6XlTEoLIDATWlpmGQPOGJU1Fa1t2J4Y2ewpFvnE8-LtiXsM_scMMakxHwnDoCfwc1SkES3nsuE8R-kpaoKPMYBVx-BGHRZFsFolq16tktUqWRGi8AP_zSN_3o_Q_a38sZoD708ByFf-dBBUNNmggc4FMEl13v2f_-GfuhnctEo_wAKx93OYsj9FVKQKq7v1zeuXCcekJi1jvwEwxaGV</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Habbig, Sandra, MD</creator><creator>Bergmann, Carsten, MD</creator><creator>Weber, Lutz T., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH</title><author>Habbig, Sandra, MD ; Bergmann, Carsten, MD ; Weber, Lutz T., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-f94fa9850ae38f9660df9f5399fee6036a9f3f33e533294268f73b1c97b206093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Atypical Hemolytic Uremic Syndrome - drug therapy</topic><topic>Atypical Hemolytic Uremic Syndrome - genetics</topic><topic>Atypical Hemolytic Uremic Syndrome - physiopathology</topic><topic>Complement Factor H - genetics</topic><topic>Humans</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Mutation</topic><topic>Nephrology</topic><topic>Pharmacogenetics - methods</topic><topic>Precision Medicine</topic><topic>Secondary Prevention</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Habbig, Sandra, MD</creatorcontrib><creatorcontrib>Bergmann, Carsten, MD</creatorcontrib><creatorcontrib>Weber, Lutz T., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Habbig, Sandra, MD</au><au>Bergmann, Carsten, MD</au><au>Weber, Lutz T., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>67</volume><issue>3</issue><spage>532</spage><epage>533</epage><pages>532-533</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26724167</pmid><doi>10.1053/j.ajkd.2015.11.009</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-6386 |
| ispartof | American journal of kidney diseases, 2016-03, Vol.67 (3), p.532-533 |
| issn | 0272-6386 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1768559755 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antibodies, Monoclonal, Humanized - administration & dosage Atypical Hemolytic Uremic Syndrome - drug therapy Atypical Hemolytic Uremic Syndrome - genetics Atypical Hemolytic Uremic Syndrome - physiopathology Complement Factor H - genetics Humans Immunologic Factors - administration & dosage Mutation Nephrology Pharmacogenetics - methods Precision Medicine Secondary Prevention Withholding Treatment |
| title | Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A07%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discontinuation%20of%20Eculizumab%20in%20a%20Patient%20With%20Atypical%20Hemolytic%20Uremic%20Syndrome%20Due%20to%20a%20Mutation%20in%20CFH&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Habbig,%20Sandra,%20MD&rft.date=2016-03-01&rft.volume=67&rft.issue=3&rft.spage=532&rft.epage=533&rft.pages=532-533&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2015.11.009&rft_dat=%3Cproquest_cross%3E1768559755%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1768559755&rft_id=info:pmid/26724167&rft_els_id=1_s2_0_S0272638615014183&rfr_iscdi=true |